Cytokinetics, Incorporated reports results for the quarter ended June 30 - Earnings Summary

Cytokinetics, Incorporated

06/08/2026 22:01

Cytokinetics, Incorporated CYTK.OQ reported a quarterly adjusted loss of $1.50​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.12.  The mean expectation of twenty two analysts for the quarter was for a loss of $1.64 per share. Wall Street expected results to range from $-2.02 to $-1.48 per share.
Revenue fell 57.1% to $28.62 million from a year ago; analysts expected $17.38 million. 
Cytokinetics, Incorporated's reported EPS for the quarter was a loss of $1.50​.
The company reported a quarterly loss of $198.76 million.
Cytokinetics, Incorporated shares had fallen by 7.4% this quarter and gained 24.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.4% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Cytokinetics, Incorporated is $105.00, about 24.9% above its last closing price of $78.85
This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.64
-1.50
Beat
Mar. 31 2026 
-1.65
-1.67
Missed
Dec. 31 2025 
-1.46
-1.50
Missed
Sep. 30 2025 
-1.58
-2.55
Missed